<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26834458</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>10</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1177-8881</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <PubDate>
              <Year>2016</Year>
            </PubDate>
          </JournalIssue>
          <Title>Drug design, development and therapy</Title>
          <ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials.</ArticleTitle>
        <Pagination>
          <StartPage>259</StartPage>
          <EndPage>276</EndPage>
          <MedlinePgn>259-76</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S89485</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Some studies have indicated the efficacy of quetiapine in the treatment of generalized anxiety disorder (GAD).</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purpose of this study was to systematically review the efficacy, acceptability, and tolerability of quetiapine in adult patients with GAD.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The SCOPUS, MEDLINE, CINAHL, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched in April 2015. All randomized controlled trials (RCTs) of GAD were considered to be included in this meta-analysis. All RCTs of quetiapine in GAD patients providing endpoint outcomes relevant to severity of anxiety, response rate, remission rate, overall discontinuation rate, or discontinuation rate due to adverse events were included. The version reports from suitable clinical studies were explored, and the important data were extracted. Measurement for efficacy outcomes consisted of the mean-changed scores of the rating scales for anxiety, and response rate.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 2,248 randomized participants in three RCTs were included. The pooled mean-changed score of the quetiapine-treated group was greater than that of the placebo-treated group and comparable to selective serotonin reuptake inhibitors (SSRIs). Unfortunately, the response and the remission rates in only 50 and 150 mg/day of quetiapine-XR (extended-release) were better than those of the placebo. Their response and remission rates were comparable to SSRIs. The rates of pooled overall discontinuation and discontinuation due to adverse events of quetiapine-XR were greater than placebo. Only the overall discontinuation rate of quetiapine-XR at 50 and 150 mg/day and the discontinuation rate due to adverse events of quetiapine-XR at 50 mg/day were comparable to SSRIs.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Based on this meta-analysis, quetiapine-XR is efficacious in the treatment of GAD in adult patients. Despite its low acceptability and tolerability, the use of 50-150 mg/day quetiapine-XR for adult GAD patients may be considered as an alternative treatment. Further well-defined studies should be conducted to warrant these outcomes.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Maneeton</LastName>
            <ForeName>Narong</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maneeton</LastName>
            <ForeName>Benchalak</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woottiluk</LastName>
            <ForeName>Pakapan</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Psychiatric Nursing Division, Faculty of Nursing, Chiang Mai University, Chiang Mai, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Likhitsathian</LastName>
            <ForeName>Surinporn</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suttajit</LastName>
            <ForeName>Sirijit</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boonyanaruthee</LastName>
            <ForeName>Vudhichai</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Srisurapanont</LastName>
            <ForeName>Manit</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>01</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Des Devel Ther</MedlineTA>
        <NlmUniqueID>101475745</NlmUniqueID>
        <ISSNLinking>1177-8881</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S3PL1B6UJ</RegistryNumber>
          <NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">acceptability</Keyword>
        <Keyword MajorTopicYN="N">efficacy</Keyword>
        <Keyword MajorTopicYN="N">generalized anxiety disorder</Keyword>
        <Keyword MajorTopicYN="N">quetiapine</Keyword>
        <Keyword MajorTopicYN="N">tolerability</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26834458</ArticleId>
        <ArticleId IdType="pmc">PMC4716733</ArticleId>
        <ArticleId IdType="doi">10.2147/DDDT.S89485</ArticleId>
        <ArticleId IdType="pii">dddt-10-259</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet. 2006;368(9553):2156–2166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17174708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuijpers P, Sijbrandij M, Koole S, Huibers M, Berking M, Andersson G. Psychological treatment of generalized anxiety disorder: a meta-analysis. Clin Psychol Rev. 2014;34(2):130–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24487344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szkodny LE, Newman MG, Goldfried MR. Clinical experiences in conducting empirically supported treatments for generalized anxiety disorder. Behav Ther. 2014;45(1):7–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24411110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitt R, Gazalle FK, Lima MS, Cunha A, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Rev Bras Psiquiatr. 2005;27(1):18–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15867979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003;2:CD003592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12804478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollack MH, Zaninelli R, Goddard A, et al.  Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62(5):350–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11411817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002;63(1):66–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11838629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160(4):749–756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12668365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stocchi F, Nordera G, Jokinen RH, et al.  Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003;64(3):250–258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12716265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allgulander C, Dahl AA, Austin C, et al.  Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry. 2004;161(9):1642–1649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15337655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(6):874–881.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16848646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varia I, Rauscher F. Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol. 2002;17(3):103–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11981350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety. 2004;19(4):234–240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15274172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davidson JR, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2005;66(11):1441–1446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16420082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katz IR, Reynolds CF, 3rd, Alexopoulos GS, Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc. 2002;50(1):18–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12028242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright A, Vandenberg C. Duloxetine in the treatment of generalized anxiety disorder. Int J Gen Med. 2009;2:153–162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2840566</ArticleId>
            <ArticleId IdType="pubmed">20360899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bystritsky A, Kerwin L, Feusner JD, Vapnik T. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder. Psychopharmacol Bull. 2008;41(1):46–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18362870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005;177(3):280–288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15258718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koponen H, Allgulander C, Erickson J, et al.  Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007;9(2):100–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1896302</ArticleId>
            <ArticleId IdType="pubmed">17607331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bose A, Korotzer A, Gommoll C, Li D. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety. 2008;25(10):854–861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18050245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11435263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rynn M, Russell J, Erickson J, et al.  Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008;25(3):182–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17311303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feighner JP. Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry. 1999;60(Suppl 22):18–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10634351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2002;63(Suppl 14):9–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12562113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr. 2008;13(7 Suppl 11):27–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18622372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Psychiatric Association  . Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013. </Citation>
        </Reference>
        <Reference>
          <Citation>Monti JM, Monti D. Sleep disturbance in generalized anxiety disorder and its treatment. Sleep Med Rev. 2000;4(3):263–276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12531169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belleville G, Cousineau H, Levrier K, St-Pierre-Delorme ME, Marchand A. The impact of cognitive-behavior therapy for anxiety disorders on concomitant sleep disturbances: a meta-analysis. J Anxiety Disord. 2010;24(4):379–386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20369395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsypes A, Aldao A, Mennin DS. Emotion dysregulation and sleep difficulties in generalized anxiety disorder. J Anxiety Disord. 2013;27(2):197–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23474909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roerig JL. Diagnosis and management of generalized anxiety disorder. J Am Pharm Assoc (Wash) 1999;39(6):811–821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10609447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canadian Agency for Drugs and Technologies in Health  . Short- and Long-Term Use of Benzodiazepines in Patients with Generalized Anxiety Disorder: A Review of Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014. </Citation>
        </Reference>
        <Reference>
          <Citation>Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927–947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15892588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509–522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11510628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):199–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18948162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandelow B, Chouinard G, Bobes J, et al.  Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010;13(3):305–320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19691907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011;31(4):418–428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21694613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychop-harmacol. 2011;26(1):11–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20881846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horacek J, Bubenikova-Valesova V, Kopecek M, et al.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389–409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16696579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303–2312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18059438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakken GV, Rudberg I, Molden E, Refsum H, Hermann M. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit. 2011;33(2):222–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21383647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldstein JM, Nyberg S, Brecher M. Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel. European Psychiatry. 2008;23(Suppl 2):S202.</Citation>
        </Reference>
        <Reference>
          <Citation>Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012;12:160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3549283</ArticleId>
            <ArticleId IdType="pubmed">23017200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012;27(1):40–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22045039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev. 2004;2:CD000967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7032613</ArticleId>
            <ArticleId IdType="pubmed">15106155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maneeton B, Maneeton N, Srisurapanont M, Chittawatanarat K. Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. Drug Des Devel Ther. 2013;7:657–667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3728270</ArticleId>
            <ArticleId IdType="pubmed">23926422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther. 2014;8:827–838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4077390</ArticleId>
            <ArticleId IdType="pubmed">25028535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13638508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins JPT, Altman DG.  Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2009.  Version 5.1.0 [updated March 2011]</Citation>
        </Reference>
        <Reference>
          <Citation>Cipriani A, Furukawa TA, Salanti G, et al.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19185342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry. 2008;69(Suppl E1):8–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18494538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deeks JJ, Higgins JPT, Altman DG.  Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2009.  Version 5.1.0 [updated March 2011]</Citation>
        </Reference>
        <Reference>
          <Citation>Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ. A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol. 2006;59(4):342–353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16549255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sterne JAC, Egger M, Moher D.  Addressing Reporting Biases. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2009.  Version 5.1.0 [updated March 2011]</Citation>
        </Reference>
        <Reference>
          <Citation>Endicott J, Svedsater H, Locklear JC. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat. 2012;8:301–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3404593</ArticleId>
            <ArticleId IdType="pubmed">22848184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montgomery SA, Locklear JC, Svedsater H, Eriksson H. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder. Int Clin Psychopharmacol. 2014;29(5):252–262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24394383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheehan DV, Svedsater H, Locklear JC, Eriksson H. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study. J Affect Disord. 2013;151(3):906–913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24135509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AstraZeneca  Safety &amp; Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs Placebo in Generalized Anxiety Disorder (TITANIUM)  [Accessed October 18, 2015].  Available fom:  https://clinicaltrials.gov/ct2/show/NCT00329264. NLM identifier: NCT00329264.</Citation>
        </Reference>
        <Reference>
          <Citation>AstraZeneca  Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder (SILVER)  [Accessed October 18, 2015].  Available from:  https://clinicaltrials.gov/ct2/show/NCT00322595. NLM identifier: NCT00322595.</Citation>
        </Reference>
        <Reference>
          <Citation>AstraZeneca  Safety &amp; Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs Placebo &amp; Active Control in Generalized Anxiety Disorder (GOLD)  [Accessed October 18, 2015].  Available from:  https://clinicaltrials.gov/ct2/show/NCT00329446. NLM identifier: NCT00329446.</Citation>
        </Reference>
        <Reference>
          <Citation>Merideth C, Cutler A, Neijber A, She F, Eriksson H. Extended release quetiapine fumarate monotherapy for generalized anxiety disorder (gad): a randomized, placebo and escitalopram-controlled study. World Psychiatry. 2009;8(Suppl 1):215. meeting: April 1–4, 2009; Florence, Italy.</Citation>
        </Reference>
        <Reference>
          <Citation>Brawman-Mintzer O, Nietert PJ, Rynn M, Rickels K. Quetiapine monotherapy in patients with generalized anxiety disorder; Paper presented at: 46th Annual NCDEU (New Clinical Drug Evaluation Unit) meeting; June 12–15, 2006; Boca Raton, FL. </Citation>
        </Reference>
        <Reference>
          <Citation>Sheehan DV, Svedsater H, Locklear J, Eriksson H. Effects of extended release quetiapine fumarate on long-term functioning and sleep quality in patients with generalized anxiety disorder (GAD) [conference abstract]; Paper presented at: 163rd Annual Meeting of the American Psychiatric Association; May 22–26, 2010; New Orleans, LA. </Citation>
        </Reference>
        <Reference>
          <Citation>Wu WY, Wang G, Ball SG, Desaiah D, Ang QQ. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China. Chin Med J (Engl) 2011;124(20):3260–3268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22088518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005;87(2–3):161–167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15982747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papadimitriou GN, Linkowski P. Sleep disturbance in anxiety disorders. Int Rev Psychiatry. 2005;17(4):229–236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16194794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stein DJ, Lopez AG. Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. Adv Ther. 2011;28(11):1021–1037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22057726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolder CR, Nelson MH, Iler CA. The effects of mirtazapine on sleep in patients with major depressive disorder. Ann Clin Psychiatry. 2012;24(3):215–224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22860241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lenze EJ, Rollman BL, Shear MK, et al.  Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA. 2009;301(3):295–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2840403</ArticleId>
            <ArticleId IdType="pubmed">19155456</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
